Menelas Pangalos Biography and Net Worth

EVP of AstraZeneca

A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s pharmaceutical discovery research and early development activities.

Since joining AstraZeneca in 2010, Mene has been instrumental in rebuilding the company’s commitment to science and scientific excellence. He has led the transformation of R&D productivity, driven deeper collaborations with academic, biotech and peer organisations, pioneered programmes to promote Open Innovation and fostered a science driven culture that rewards great science and truth-seeking behaviours.

Mene retains an active interest in neurodegenerative disease and neuropharmacology and continues to mentor post docs and PhD students.

Mene has published more than 150 peer-reviewed articles in scientific journals and is an internationally renowned expert in neuroscience and drug discovery. He is a leading figure in UK science, serving on several Boards including the of The Francis Crick Institute, Cambridge University’s Judge Business School and Dizal Pharma. Mene has been elected a Fellow of the Royal Society where he is also a member of their Science, Industry and Translation Committee, and holds Fellowships with the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall – University Cambridge. He sits on the council of the Medical Research Council (MRC), co-chairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the UK Life Sciences Industrial Strategy Implementation Board. Mene was recognised in the New Year 2020 Honours list with a knighthood from Her Majesty The Queen of United Kingdom of Great Britain and Northern Ireland, for his services to UK science.

Mene oversaw the creation of AstraZeneca’s new R&D Centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

How do I contact Menelas Pangalos?: The corporate mailing address for Dr. Pangalos and other AstraZeneca executives is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. AstraZeneca can also be reached via phone at 442037495000 and via email at [email protected]. Learn More on Menelas Pangalos' contact information.
Has Menelas Pangalos been buying or selling shares of AstraZeneca?: Menelas Pangalos has not been actively trading shares of AstraZeneca during the last quarter. Learn More on Menelas Pangalos' trading history.
Who are AstraZeneca's active insiders?: AstraZeneca's insider roster includes Katarina Ageborg (EVP of Sustainability), Pam Cheng (EVP of Operations & Information Technology and Member of External Sustainability Advisory Board ), Marc Dunoyer (CEO of Alexion & Chief Strategy Officer ), Menelas Pangalos (EVP ), Aradhana Sarin (CFO & Exec. Director ), and Pascal Soriot (Executive Director and Chief Executive Officer ). Learn More on AstraZeneca's active insiders.

Menelas Pangalos Insider Trading History at AstraZeneca

Menelas Pangalos Buying and Selling Activity at AstraZeneca

AstraZeneca Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $63.74

$63.56

$63.89

50 Day Range

MA: $73.99

$63.20

$79.58

2 Week Range

Now: $63.74

$60.47

$87.68

Volume

2,106,152 shs

Average Volume

5,287,552 shs

Market Capitalization

$197.63 billion

P/E Ratio

30.50

Dividend Yield

1.54%

Beta

0.47

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad